Technical and procedural updates only. The v3 version reflects the bill's passage from the House of Representatives to the Senate and includes the name of the House Clerk. There are no substantive policy changes to the text of the bill between v2 and v3.
HALT Fentanyl Act
- Sponsor
- Rep. Griffith, H. Morgan [R-VA-9]
- Committees
- Judiciary Committee (primary)
- Last action
- Feb 10, 2025
Bottom line
This bill aims to combat the fentanyl crisis by permanently scheduling fentanyl analogues while simultaneously easing research barriers for Schedule I substances.
What it actually does
The HALT Fentanyl Act permanently places all fentanyl-related substances into Schedule I of the Controlled Substances Act, subjecting them to the highest level of federal control and criminal penalties. Concurrently, it streamlines the research registration process for Schedule I substances, aiming to accelerate scientific study into these compounds, particularly for federally funded or FDA-approved investigational drugs. It also clarifies existing legal interpretations regarding fentanyl analogues.
Proponents argue
Proponents argue that permanently scheduling fentanyl-related substances is a critical step to close legal loopholes that drug traffickers exploit, ensuring that new variations of fentanyl are immediately subject to criminal penalties. They also contend that streamlining research requirements for Schedule I drugs will accelerate the development of treatments and antidotes, addressing the public health crisis more effectively.
Opponents contend
Opponents may argue that a blanket scheduling approach could hinder legitimate scientific and medical research by casting too wide a net, potentially delaying the discovery of new therapeutic uses or understanding of these complex substances, despite the bill's research streamlining provisions. Some may also raise concerns about the broad definition potentially encompassing substances with unknown or minimal abuse potential, and the impact of enhanced penalties on mass incarceration.
The bill is moderately complex due to its legal and chemical terminology, requiring careful reading to understand its full implications, especially for the scheduling definition and research changes.
Section 2, amending 21 U.S.C. 812(c) (Schedule I)
Permanent Class Scheduling of Fentanyl-Related Substances
This provision adds a new category to Schedule I of the Controlled Substances Act, permanently classifying any substance structurally related to fentanyl as a Schedule I controlled substance. This means such substances are deemed to have a high potential for abuse and no currently accepted medical use, subjecting them to the strictest federal controls and penalties. The definition includes various chemical modifications to the fentanyl structure, unless specifically exempted or listed in another schedule.
Supporters argue
Supporters argue this provision is crucial for closing a 'loophole' that allows illicit manufacturers to slightly alter fentanyl's chemical structure to create new, unregulated, and dangerous substances. Permanent scheduling ensures that these new variants are immediately illegal, preventing traffickers from evading prosecution and protecting public health.
Critics contend
Some critics, while acknowledging the dangers of fentanyl, may argue that a broad, permanent class scheduling could inadvertently stifle legitimate scientific research into these compounds, even with the bill's research streamlining provisions. They might suggest that a more targeted or temporary scheduling approach would allow for greater flexibility in scientific inquiry.
Tradeoffs
The provision balances the urgent need to combat illicit fentanyl trafficking with potential concerns about the breadth of chemical definitions and their implications for future scientific and medical research.
Section 3(a), adding new subsection (n) to 21 U.S.C. 823
Expedited Registration for Schedule I Research
This provision creates a faster registration process for practitioners conducting research with Schedule I controlled substances, specifically for drugs with an FDA investigational use exemption (IND) or research funded by HHS, DoD, or VA. Existing Schedule I or II researchers can notify the Attorney General and begin research after 30 days. New researchers can submit a notice, which the Attorney General must process within 45 days.
Section 3(b) and 3(c), amending 21 U.S.C. 822(c) and 822(e)
Simplified Registration for Research Institutions and Multiple Sites
This provision allows agents or employees of a research institution to conduct research under the registration of another registered researcher at that institution, provided certain conditions are met (e.g., notification to the Attorney General, attribution of acts to the registered researcher). It also permits a single registration for research conducted across multiple sites within the same city or county, as long as the sites are under the control of the same institution and the Attorney General is notified.
Section 3(e), adding new subsection (h) to 21 U.S.C. 822
Continuation of Research on Substances Newly Added to Schedule I
This provision allows researchers already registered for Schedule I substances to continue research on a substance newly added to Schedule I, provided they submit a new or modified application within 90 days. Research can continue until the application is withdrawn or denied, with expedited hearings for denials, ensuring continuity of ongoing studies.
Section 3(g), adding new subsection (o) to 21 U.S.C. 823
Transparency Regarding Special Procedures for Research
This provision requires the Attorney General to publicly disclose any instances where an application to conduct research with a controlled substance is subject to different processes or criteria than other substances in the same schedule. This includes identifying the substances, the specific processes/criteria, and how they differ, with immediate public posting on the DEA website.
Section 6, amending 21 U.S.C. 841(b)(1) and 21 U.S.C. 960(b)
Enhanced Penalties for Fentanyl-Related Substances
This provision explicitly adds 'fentanyl-related substance' to existing penalty provisions in the Controlled Substances Act and the Controlled Substances Import and Export Act. This ensures that individuals involved in manufacturing, distributing, or importing fentanyl-related substances face the same severe criminal penalties as those dealing with fentanyl itself or its direct analogues, including mandatory minimum sentences based on quantity.
Section 7(b) clarifies that the Act's amendments do not imply that fentanyl-related substances were not analogues of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide (fentanyl) before the Act's enactment, for the purpose of applying existing penalty provisions. Section 7(c) expresses a Sense of Congress agreeing with the interpretation of the Controlled Substances Act in United States v. McCray, 346 F. Supp. 3d 363 (2018).
Section 7(b) and 7(c)
Why it matters:This is standard legislative practice for clarifying legal intent and addressing potential retroactive application issues, rather than an attempt to hide a provision. It aims to prevent misinterpretation of the new law's impact on past conduct.
Case for: Supporters argue this clarification is vital to ensure that past prosecutions of fentanyl analogue traffickers remain valid and that the new law doesn't inadvertently create a defense for prior illicit activities. The McCray case affirmed that fentanyl analogues could be prosecuted under the existing analogue statute.
Case against: While not directly opposed, some legal scholars might debate the necessity or scope of such a rule of construction, or its potential impact on due process arguments in specific cases, though the intent is to maintain continuity in enforcement.
Estimated impact: Significant for ongoing or past legal cases involving fentanyl analogues, ensuring continuity in federal drug enforcement policy.